Inflarx N.V. (NASDAQ:IFRX) on Focus After Report of Less Shorts



November 23, 2018 – By Mark Babin

The stock of Inflarx N.V. (NASDAQ:IFRX) registered a decrease of 0.32% in short interest. IFRX’s total short interest was 250,200 shares in November as published by FINRA. Its down 0.32% from 251,000 shares, reported previously. With 11,000 shares average volume, it will take short sellers 23 days to cover their IFRX’s short positions. The short interest to Inflarx N.V.’s float is 3.46%.

The stock increased 0.75% or $0.21 during the last trading session, reaching $28.11. About 13,851 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since November 23, 2017 and is . It has underperformed by 15.62% the S&P500.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $721.36 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Benzinga.com which released: “35 Stocks Moving In Monday’s Mid-Day Session” on November 19, 2018, also Nasdaq.com with their article: “InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing” published on October 30, 2018, Globenewswire.com published: “InflaRx NV Reports Third Quarter 2018 Financial & Operating Results” on November 21, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Seekingalpha.com and their article: “InflaRx down 14%” published on November 19, 2018 as well as Streetinsider.com‘s news article titled: “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018” with publication date: November 14, 2018.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *